Month: September 2020

VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) — Rockridge Resources Ltd. (TSX-V: ROCK) (OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge” or the “Company”) is pleased to announce that its 3,000 metre minimum drill program has commenced at its high-grade Raney Gold Project located southwest of Timmins, Ontario, Canada (the “Raney Gold Project” or “Property”). The drill program will include approximately 11 drill holes which will range in depth between 200 metres and 350 metres to test the strike and down-plunge extent of the high-grade intercepts identified during the previous drilling programs. Raney Gold Project Location Map:http://www.rockridgeresourcesltd.com/_resources/maps/location_map_may2020a.jpg“We are excited to continue drilling the high-priority targets at our strategically located Raney Gold Project.”...

TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 12 cents per unit for the month of September. The distribution will be payable on October 7, 2020 to unitholders of record as at September 30, 2020.About RioCanRioCan is one of Canada’s largest real estate investment trusts. RioCan owns, manages and develops retail-focused, increasingly mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at June 30, 2020, our portfolio is comprised of 221 properties with an aggregate net leasable area of approximately 38.6 million square feet (at RioCan’s interest) including office, residential rental and 15 development properties. To learn more about us, please visit www.riocan.com.Information...

HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) — Exterran Corporation (NYSE: EXTN) (“Exterran” or the “Company”) updated its third quarter and full year 2020 guidance.Andrew Way, Exterran’s President and Chief Executive Officer commented, “The third quarter, thus far, has delivered stronger operational performance than prior guidance, driven by productivity and additional cost focus. With this performance we are increasing our third quarter 2020 adjusted EBITDA guidance to around $35 million and as a result, we are also adjusting the full year guidance range up to $125-140 million of adjusted EBITDA.”About Exterran CorporationExterran Corporation (NYSE: EXTN) is a global systems and process company offering solutions in the oil, gas, water and power markets. We are a leader in natural gas processing and treatment and compression products...

Ferratum Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Frederik StrangePosition: Member of the Board/Deputy memberIssuer: Ferratum OyjLEI: 74370078YLPFWHE33716Notification type: INITIAL NOTIFICATIONReference number: 74370078YLPFWHE33716_20200915124328_8____________________________________________Transaction date: 2020-09-14Venue: XETRA – REGULIERTER MARKT (XETA)Instrument type: SHAREISIN: FI4000106299Nature of the transaction: ACQUISITIONTransaction details(1): Volume: 1,650 Unit price: 4.8 EURAggregated transactions(1): Volume: 1,650 Volume weighted average price: 4.8 EUR

2020 Interim Results     – Vectura reports 2020 financial performance on-track and demonstrates progress on strategy execution with 12 new CDMO deals signed year to date –  Chippenham, UK – 15 September 2020: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”, “the Company”), an industry-leading specialist inhalation CDMO, today announces its unaudited Interim Results for the six-months ended 30 June 2020.Financial summaryOperational highlightsExecuting on strategy to become an industry-leading inhalation CDMONew Business Development team now established with presence in East and West Coast US, Europe and UK4 New CDMO contracts signed, with a further 8 signed since the period end; £3m-£5m revenue impact, expected in H2 2020Operational transformation continues throughout COVID-19 pandemicResilient base business...

AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103DUBLIN, Ireland, and Boston MA, September 15 2020,  Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products (“COMP”) has adopted a positive opinion for orphan designation for the use of AP103 in Epidermolysis Bullosa (“EB”). AP103 is based on Amryt’s gene-therapy platform technology and offers a potential treatment for patients with Dystrophic Epidermolysis Bullosa (“DEB”), a subset of EB.  Orphan drug designation in the EU is granted by the European...

Tuebingen, Germany and Houston, Texas, September 15, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the appointment of Eliot Forster, PhD, to its Board of Directors. Forster currently serves as Chief Executive Officer (CEO) at bispecific antibody developer, F-star Therapeutics, and Non-Executive Chairman of Avacta plc. He brings to Immatics extensive experience, including leadership of trailblazing biopharmaceutical companies in the field of immuno-oncology and others. He will further strengthen Immatics’ Board as the company develops its pipeline of T cell receptor (TCR)-based therapeutics.Peter Chambré, Chairman of Immatics’ Board of Directors commented: “Being able to attract Eliot to the...

Tübingen, Deutschland und Houston, Texas, 15. September 2020 – Immatics N.V. (NASDAQ: IMTX; „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die Behandlung von Krebs fokussiert, gab heute die Berufung von Dr. Eliot Forster, in seinen Aufsichtsrat bekannt. Eliot Forster ist aktuell als Chief Executive Officer (CEO) von F-Star Therapeutics, einer Firma zur Entwicklung bispezifischer Antikörper, tätig – sowie als Non-Executive Chairman bei Avacta plc. Immatics wird von seiner umfangreichen Erfahrung insbesondere in der Leitung bahnbrechender biopharmazeutischer Unternehmen im Bereich der Immunonkologie sowie anderer Indikationen profitieren. Mit seiner Expertise wird er Immatics’ Aufsichtsrat verstärken, um die Firma bei der weiteren Entwicklung seiner T-Zell-Rezeptor (TCR)-basierten...

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first subjects in a Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan).The Phase 1 trial, which is being conducted by Kyorin, is a placebo-controlled study to evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in 32 healthy Japanese male volunteers. Assuming successful completion of the study, Kyorin would then be able to initiate patient trials in interstitial lung diseases (ILDs) in Japan.  “ATYR1923 is a potential first-in-class...

CALABASAS, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Resonate Blends, Inc. (OTCQB:KOAN), a cannabis holding company centered on valued-added holistic Wellness and Lifestyle brands, announces today the selection of Way To Blue as the marketing firm for its Koan family of wellness lifestyle blends.Way To Blue, is an award-winning, global, integrated communications agency working with consumer, lifestyle, media and entertainment companies, developing digitally-led strategic brand communications.“We are dedicated as a company to ‘Mastering the Art of Experience.’ In order to achieve that, we are innovating with our products, distribution, communication and education. To that end, we are adopting a digital native national brand strategy for our Koan product family so that every aspect of our relationship to our clients is carefully curated,...